---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-010013"
form_type: "8-K"
ticker: "PRPH"
cik: "0000868278"
company_name: "ProPhase Labs, Inc."
filed_at: "2024-03-15T23:59:59+00:00"
generated_at: "2026-06-04T18:25:11.158172+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ProPhase Labs reports FY 2023 net loss of $16.8M; revenue down 63% to $45.2M

## Summary
- Net loss of $16.8M ($0.98 per share) vs. net income of $18.5M ($1.17 per share) in FY 2022.
- Revenue fell 63% to $45.2M due to COVID-19 testing decline; diagnostic services revenue dropped $83.5M.
- Nebula Genomics signed international B2B deal with MenaDNA; potential $10-20M annual revenue from another agreement.
- Pharmaloz capacity guidance raised to $45M run-rate by Q3 2024, then $80-100M by H1 2025; existing customers accepted 15.2% price increase.
- BE-Smart esophageal cancer test on track for H2 2024 commercialization; Equivir trial interim results showed 68% of respiratory incidents in placebo group.

## SEC filing metadata
- accession: 0001493152-24-010013
- form_type: 8-K
- ticker: PRPH
- cik: 0000868278
- company_name: ProPhase Labs, Inc.
- filed_at: 2024-03-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/868278/000149315224010013/0001493152-24-010013-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/868278/000149315224010013/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-010013
- JSON: https://secwatch.observer/filing/0001493152-24-010013.json
- Plain text: https://secwatch.observer/filing/0001493152-24-010013.txt

## Key facts
- Earnings Releases
  ProPhase Labs, Inc. reported financial results for the full-year ended December 31, 2023.
  - Period: the full-year ended December 31, 2023
  - Result: reported results
  source text: On March 15, 2024, ProPhase Labs, Inc. (the “Company”) issued a press release announcing its financial results for the year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/868278/000149315224010013/0001493152-24-010013-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.